Search results for "androgeni"

showing 10 items of 94 documents

Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency.

2016

AbstractGrowth hormone (GH) plays a role in the regulation of ovarian function but there are limited data in women with GH deficiency (GHD). Our aim was to evaluate the features of polycystic ovarian syndrome (PCOS) in women with previous GHD.Data of 22 adolescents previously GH-treated (group A) were compared with those of 22 women with classical PCOS (group B) and 20 controls (group C).: Group A showed higher testosterone (p=0.048) and prevalence of menstrual irregularities (p<0.001) than group C. Compared to the group B, group A showed lower diastolic blood pressure (p=0.004), degree of hirsutism (p=0.005), testosterone (p=0.003) and prevalence of polycsytic ovaries (POC) morphology (…

MaleHirsutismmedicine.medical_specialtyAdolescentChildhood growthEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGroup AGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinePrevalenceHumansMedicineTestosteroneProspective StudiesChildGrowth DisordersMenstruation DisturbancesTestosteronehirsutism030219 obstetrics & reproductive medicineEstradiolHuman Growth Hormonebusiness.industryPrognosismedicine.diseaseGrowth hormone polycystic ovarian syndromeEndocrinologyBlood pressureItalyCase-Control StudiesPediatrics Perinatology and Child HealthFemaleHyperandrogenismbusinessBiomarkersGH DeficiencyFollow-Up StudiesPolycystic Ovary SyndromeHormone
researchProduct

Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues

2008

Predictive quantitative structure-activity relationship (QSAR) models of anabolic and androgenic activities for the testosterone and dihydrotestosterone steroid analogues were obtained by means of multiple linear regression using quantum and physicochemical molecular descriptors (MD) as well as a genetic algorithm for the selection of the best subset of variables. Quantitative models found for describing the anabolic (androgenic) activity are significant from a statistical point of view: R2 of 0.84 (0.72 and 0.70). A leave-one-out cross-validation procedure revealed that the regression models had a fairly good predictability [q2 of 0.80 (0.60 and 0.59)]. In addition, other QSAR models were …

MaleQuantitative structure–activity relationshipAnabolismStereochemistrymedicine.medical_treatmentClinical BiochemistryAnabolic and androgenic activitiesQSAR modelQuantitative Structure-Activity RelationshipPharmaceutical ScienceBiochemistrySteroidAnabolic AgentsMolecular descriptorDrug DiscoveryLinear regressionmedicineCluster AnalysisHumansComputer SimulationTestosteroneMolecular BiologyChemistryOrganic ChemistryDihydrotestosteroneModels ChemicalGenetic algorithmDihydrotestosteroneAndrogensQuantum and physicochemical molecular descriptorMolecular MedicineTestosterone and dihydrotestosterone steroid analoguesAlgorithmsAnabolic steroidApplicability domainmedicine.drugBioorganic and Medicinal Chemistry 16: 6448-6459 (2008)
researchProduct

The spectrum of androgen excess disorders.

2006

A better understanding of the different phenotypes and of their endocrine and metabolic characteristics permits investigators to distinguish three main androgen excess disorders: classic polycystic ovary syndrome (PCOS), mild ovulatory PCOS, and idiopathic hyperandrogenism. These androgenic phenotypes differ more for the severity of the endocrine and metabolic alteration than for the etiopathogenetic mechanisms. The appearance of a particular androgenic phenotype is determined by a sum of genetic and environmental factors, but mostly by body weight.

Malemedicine.medical_specialtymedicine.drug_classBiologyAndrogen ExcessDiagnosis DifferentialInsulin resistancePolycystic ovary syndrome hyperandrogenism androgen excess insulin resistance idiopathic hirsutismInternal medicinemedicineEndocrine systemHumanshirsutismHyperandrogenismObstetrics and Gynecologymedicine.diseaseAndrogenPhenotypePolycystic ovaryEndocrinologyReproductive MedicinePractice Guidelines as TopicAndrogensFemaleHyperandrogenismPolycystic Ovary SyndromeFertility and sterility
researchProduct

Polycystic ovary syndrome

2016

Polycystic ovary syndrome (PCOS) affects 5-20% of women of reproductive age worldwide. The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology (PCOM) - with excessive androgen production by the ovaries being a key feature of PCOS. Metabolic dysfunction characterized by insulin resistance and compensatory hyperinsulinaemia is evident in the vast majority of affected individuals. PCOS increases the risk for type 2 diabetes mellitus, gestational diabetes and other pregnancy-related complications, venous thromboembolism, cerebrovascular and cardiovascular events and endometrial cancer. PCOS is a diagnosis of exclusion, based primarily on the p…

OvulationHirsutismmedicine.medical_specialtyendocrine system diseases030209 endocrinology & metabolismOvaryPathogenesis03 medical and health sciences0302 clinical medicineInsulin resistanceSDG 3 - Good Health and Well-beingRisk FactorsInternal medicineAcne VulgarismedicineHumansCongenital adrenal hyperplasiaObesityAbdominal obesityhirsutism030219 obstetrics & reproductive medicinebusiness.industryOvaryHyperandrogenismAlopeciaGeneral Medicinemedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologymedicine.anatomical_structureAndrogensQuality of LifeFemalemedicine.symptomHyperandrogenismbusinessPolycystic Ovary SyndromeNature Reviews Disease Primers
researchProduct

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

2009

Abstract OBJECTIVE: To review all available data and recommend a definition for polycystic ovary syndrome (PCOS) based on published peer-reviewed data, whether already in use or not, to guide clinical diagnosis and future research. DESIGN: Literature review and expert consensus. SETTING: Professional society. PATIENTS: None. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): A systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, to identify studies evaluating the epidemiology or phenotypic aspects of PCOS. RESULT(S): The Task Force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and c…

Ovulationmedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesMEDLINEPCOS Fertility Anovulation Menstrual irregularities Obesity Hyperandrogenism Ovarian function Ovarian ultrasoundsSettore MED/13 - EndocrinologiaDiagnosis DifferentialPredictive Value of TestsIntervention (counseling)Terminology as TopicEpidemiologymedicineHealth Status IndicatorsHumanshirsutismMenstruation DisturbancesOvarian Function TestsGynecologyEvidence-Based Medicinebusiness.industryHyperandrogenismOvaryObstetrics and GynecologyEvidence-based medicinemedicine.diseasePolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsPhenotypeReproductive MedicineFemalebusinessHyperandrogenismBiomarkersMedical literatureClinical psychologyPolycystic Ovary SyndromeFertility and sterility
researchProduct

Estroprogestins and cardiovascular risk in Polycystic Ovary Syndrome

2013

Because PCOS women present an increased cardiovascular risk, the safety of estroprogestin treatment is debated and contrasting data have been reported. However, cardiovascular risk is not the same in all PCOS women and individual cardiovascular risk should be assessed before staring any estroprogestin treatment. The available data show that products containing both second generation and third generation progestins (including drosperinone and cyproterone acetate) represent a safe treatment in PCOS patients with regular cardiovascular risk. In PCOS patients with increased cardiovascular risk, a careful choice of estroprogestin product is needed and cardiovascular risk should be monitored duri…

PCOS Estroprogestins Cardiovascular risk contraception hyperandrogenismSettore MED/40 - Ginecologia E OstetriciaSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/13 - Endocrinologia
researchProduct

Introduction to the special issue: 2012 AE-PCOS meeting

2013

No abstract available

PharmacologyEndocrinologyOrganic ChemistryClinical BiochemistryPCOS Cardiovascular risk infertility hyperandrogenism insulin resistanceMolecular BiologyBiochemistrySettore MED/40 - Ginecologia E OstetriciaSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/13 - Endocrinologia
researchProduct

Editorial

2012

PharmacologyEndocrinologyOrganic ChemistryClinical BiochemistryPCOS Hyperandrogenism Insulin resistanceSettore MED/40 - Ginecologia E OstetriciaMolecular BiologyBiochemistrySettore MED/13 - EndocrinologiaSteroids
researchProduct

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

2006

Abstract Objective: The Androgen Excess Society (AES) charged a task force to review all available data and recommend an evidence-based definition for polycystic ovary syndrome (PCOS), whether already in use or not, to guide clinical diagnosis and future research. Participants: Participants included expert investigators in the field. Evidence: Based on a systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, we tried to identify studies evaluating the epidemiology or phenotypic aspects of PCOS. Consensus Process: The task force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and crit…

Position statementmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismBiochemistry (medical)Clinical BiochemistryHyperandrogenismMEDLINEGuidelinemedicine.diseaseAndrogen ExcessBiochemistryPolycystic ovaryEndocrinologyEndocrinologyInternal medicineEpidemiologyMedicinebusinessMedical literatureThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause

2013

Context: Polycystic ovary syndrome (PCOS) is diagnosed during the reproductive years when women present with 2 of 3 of the following criteria: 1) irregular menstrual cycles or anovulation, 2) hyperandrogenism, and 3) PCO morphology. However, there is evidence that PCOS can be identified from early infancy to puberty based on predisposing environmental influences. There is also increasing information about the PCOS phenotype after menopause. The goal of this review is to summarize current knowledge about the appearance of PCOS at different life stages and the influence of reproductive maturation and senescence on the PCOS phenotype. Evidence: PubMed, the bibliography from the Evidence-Based …

Senescencemedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryContext (language use)BiochemistrySettore MED/13 - EndocrinologiaAnovulationEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaInternal medicinemedicinePregnancybusiness.industryPolycystic ovary syndrome (PCOS)Biochemistry (medical)Hyperandrogenismnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryPCOS Pregnancy infancy puberty menopause obesity AMH cardiovascular risk birth weightSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsMenopauseEndocrinologybusiness
researchProduct